Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Cecchini

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2015
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38Reena S Cecchini, Sandra M Swain, Joseph P Costantino, et al.
NPJ Breast Cancer|May 21, 2021
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumabPatricia A Ganz, Reena S Cecchini, Louis Fehrenbacher, et al.
Journal of the National Cancer Institute|November 7, 2020
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced AmenorrheaKathryn J Ruddy, Daniel J Schaid, Anthony Batzler, et al.
Journal of the National Cancer Institute|November 17, 2005
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyBernard Fisher, Joseph P Costantino, D Lawrence Wickerham, et al.
JNCI Cancer Spectrum|April 2, 2025
Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trialHanna Bandos, Sungjin Kim, N Lynn Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trialPatricia A Ganz, Stephanie R Land, Charles E Geyer, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.
Future Oncology (London, England)|June 27, 2025
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancerLior Z Braunstein, Melissa P Mitchell, Hanna Bandos, et al.
Lancet (London, England)|December 22, 2015
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trialPatricia A Ganz, Reena S Cecchini, Thomas B Julian, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2015
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38Reena S Cecchini, Sandra M Swain, Joseph P Costantino, et al.
NPJ Breast Cancer|May 21, 2021
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumabPatricia A Ganz, Reena S Cecchini, Louis Fehrenbacher, et al.
Journal of the National Cancer Institute|November 7, 2020
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced AmenorrheaKathryn J Ruddy, Daniel J Schaid, Anthony Batzler, et al.
Journal of the National Cancer Institute|November 17, 2005
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyBernard Fisher, Joseph P Costantino, D Lawrence Wickerham, et al.
JNCI Cancer Spectrum|April 2, 2025
Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trialHanna Bandos, Sungjin Kim, N Lynn Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trialPatricia A Ganz, Stephanie R Land, Charles E Geyer, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.
Future Oncology (London, England)|June 27, 2025
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancerLior Z Braunstein, Melissa P Mitchell, Hanna Bandos, et al.
Lancet (London, England)|December 22, 2015
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trialPatricia A Ganz, Reena S Cecchini, Thomas B Julian, et al.
Pageof 15